EBV vaccine after stem cell transplant
Part of Blood & lymphatic, Immune system & allergy, Infections clinical trials.
This trial tests a vaccine that may help prevent diseases caused by the Epstein-Barr virus (EBV) after a stem cell transplant. It could lower the risk of infections and related complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 14 years old or older.
- You have had or are about to have a stem cell transplant from a donor.
- You are willing to participate and sign a consent form.
- You do not have a history of severe allergic reactions to vaccines.
- You do not have active graft-versus-host disease (a condition where donor cells attack your body) at the time of screening.
- You do not have severe heart, liver, or kidney problems, or a fever above 38°C in the last 3 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new mRNA-based immunotherapy for diseases caused by the Epstein-Barr virus (EBV), such as certain cancers and conditions after a stem cell transplant. The treatment aims to help your immune system fight the virus and the disease.
This trial tests whether special immune cells (called EBV-TCR-T cells) can help clear the Epstein-Barr virus in people who still have high virus levels after a stem cell transplant. It's an experimental therapy for those whose virus hasn't responded to standard care.
This trial tests an investigational mRNA vaccine (WGc-043) that aims to help your immune system fight EBV-positive lymphoma cells. If you have tried standard treatments and your lymphoma is still active, this vaccine might offer a new option.
This trial tests a new treatment using specially trained immune cells (TCR-T cells) to fight Epstein-Barr virus (EBV) infections that can occur after a stem cell transplant for blood cancer. It may help control the virus and prevent complications.
This trial tests a special immune cell therapy (EBV-AST) for people who have high levels of Epstein-Barr virus (EBV) in their blood after a stem cell transplant. The goal is to see if it can safely control the virus and prevent related complications.
This trial tests whether specially trained donor immune cells can prevent a common viral infection after a stem cell transplant. It is for people at high risk of the virus, which can cause serious problems.
Hear when a new Patients After Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.